The management of localized breast cancer often involves a trimodality approach of surgery and radiation therapy with or without systemic treatment. During this past decade, substantial advances were made to minimize aggressive and radical surgery, reduce radiation-related toxicity, and use precision medicine to forego systemic chemotherapy in select estrogen receptor–positive patients. In the era of targeted therapies for overexpressed markers, such as human epidermal growth factor receptor 2 gene and the use of neoadjuvant systemic treatments to downstage and improve overall outcomes, there has been an increase in rates of clinical complete response (CR) observed before surgical evaluation and confirmed postoperatively as pathological CR.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Oladeru OT, Hirsch AE, Ko NY. Trends in Deescalation of Localized Breast Cancer Treatment and Caution for the Most Vulnerable Patients—A Look Back on the Decade That Was. JAMA Oncol. Published online September 24, 2020. doi:10.1001/jamaoncol.2020.1821
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: